Formulations comprising jorumycin-, renieramycin-, safracinor saframycin-related compounds for treating proliferative diseases

Details for Australian Patent Application No. 2006310260 (hide)

Owner Pharma Mar, S.A.

Inventors Tobio Barreira, Maria; Calvo Salve, Pilar

Agent Griffith Hack

Pub. Number AU-B-2006310260

PCT Pub. Number WO2007/052076

Priority 0522082.7 31.10.05 GB

Filing date 30 October 2006

Wipo publication date 10 May 2007

Acceptance publication date 9 August 2012

International Classifications

A61K 9/00 Medicinal preparations characterised by special physical form

A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems

A61K 47/26 Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carbohydrates

A61P 35/00 Antineoplastic agents

A61K 9/19 Medicinal preparations characterised by special physical form - lyophilised

Event Publications

1 May 2008 PCT application entered the National Phase

  PCT publication WO2007/052076 Priority application(s): WO2007/052076

22 May 2008 Amendment Made

  The nature of the amendment is: Remove Co-Inventor: Graham Keith Ruffles

31 May 2012 Amendment Made

  The nature of the amendment is: Amend the invention title to read Formulations comprising jorumycin-, renieramycin-, safracinor saframycin-related compounds for treating proliferative diseases 2007

9 August 2012 Application Accepted

  Published as AU-B-2006310260

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006310265-Bacterial growth enhancer

2006310257-Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (HDAC) inhibitors